Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2006 2
2007 1
2008 1
2009 2
2010 5
2011 5
2012 2
2013 3
2014 7
2015 4
2016 6
2017 4
2018 5
2019 2
2020 3
2021 5
2022 9
2023 15
2024 17
2025 11
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D. Smolen JS, et al. Among authors: edwards cj. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10. Ann Rheum Dis. 2023. PMID: 36357155 Free article.
Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were all considered. ...
Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were all c …
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.
Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G. Mebazaa A, et al. Among authors: edwards c. Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7. Lancet. 2022. PMID: 36356631 Clinical Trial.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.
Smolen JS, Edwards CJ, Konzett V, Laskou F, Aletaha D, Caporali R, Dörner T, Hyrich KL, Mateus E, Pope JE, Primdahl J, de Souza S, Stamm T, Takeuchi T, van der Heijde D, Verschueren P, Winthrop KL, Alvaro-Gracia JM, Askling J, Bathon J, Buch MH, Burmester GR, Codreanu C, Conaghan PG, Cutolo M, Fautrel B, Fonseca J, Gossec L, Haavardsholm E, Hetland ML, Iagnocco A, Juge PA, Li Z, Moe RH, Nash P, Poór G, Rubbert-Roth A, Sobrin RDS, Schulze-Koops H, Shumnalieva R, Senolt L, Silva-Fernandez L, Strangfeld A, Taylor P, Turesson C, van Duuren E, de Wit M, Xavier R, Kerschbaumer A, Landewé RBM. Smolen JS, et al. Among authors: edwards cj. Ann Rheum Dis. 2026 Jun;85(6):991-1009. doi: 10.1016/j.ard.2026.01.023. Epub 2026 Mar 13. Ann Rheum Dis. 2026. PMID: 41826212 Free article.
Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were considered. ...
Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were consi …
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A, Kerschbaumer A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, Edwards CJ, Verschueren P, de Souza S, Pope J, Takeuchi T, Hyrich K, Winthrop KL, Aletaha D, Stamm T, Schoones JW, Landewé RBM. Sepriano A, et al. Among authors: edwards cj. Ann Rheum Dis. 2023 Jan;82(1):107-118. doi: 10.1136/ard-2022-223357. Epub 2022 Nov 14. Ann Rheum Dis. 2023. PMID: 36376026 Free article.
The risk of malignancies was similar across bDMARDs (five studies) and with tofacitinib compared with bDMARDs (one study, low RoB). The risk of major adverse cardiovascular events (MACE) was similar with bDMARDs and tofacitinib (two studies, one low RoB). Thirty studies re …
The risk of malignancies was similar across bDMARDs (five studies) and with tofacitinib compared with bDMARDs (one study, low RoB). The risk …
Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity.
Marks JL, Colebatch AN, Buchbinder R, Edwards CJ. Marks JL, et al. Among authors: edwards cj. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD008952. doi: 10.1002/14651858.CD008952.pub2. Cochrane Database Syst Rev. 2011. PMID: 21975789
In this study, the presence of cardiovascular disease increased the likelihood of a further cardiovascular event three-fold. Patients with two or more cardiovascular comorbidities showed a two-fold increased likelihood of adverse cardiovascular events. …
In this study, the presence of cardiovascular disease increased the likelihood of a further cardiovascular event three-fold. P …
Guideline-Directed Medical Therapy Use in the STRONG-HF Trial.
Zhang X, Davison B, Adamo M, Arrigo M, Biegus J, Chioncel O, Cohen Solal A, Cotter G, Edwards C, Kimmoun A, Lam CSP, Mebazaa A, Metra M, Novosadova M, Pang PS, Sliwa K, Takagi K, Voors AA, Ezekowitz JA. Zhang X, et al. Among authors: edwards c. Circ Heart Fail. 2025 Sep;18(9):e012716. doi: 10.1161/CIRCHEARTFAILURE.124.012716. Epub 2025 Jul 3. Circ Heart Fail. 2025. PMID: 40605744 Clinical Trial.
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF.
Davison BA, Senger S, Sama IE, Koch GG, Mebazaa A, Dickstein K, Samani NJ, Metra M, Anker SD, Cleland JG, Ng LL, Mordi IR, Zannad F, Filippatos GS, Hillege HL, Ponikowski P, van Veldhuisen DJ, Lang CC, van der Meer P, Núñez J, Bayés-Genís A, Edwards C, Voors AA, Cotter G. Davison BA, et al. Among authors: edwards c. Eur J Heart Fail. 2021 Jan;23(1):43-57. doi: 10.1002/ejhf.2077. Epub 2021 Jan 22. Eur J Heart Fail. 2021. PMID: 33340221 Free article. Review.
Safety and efficacy intravenous istaroxime up to 60 hours for patients with pre-cardiogenic shock.
Biegus J, Mebazaa A, Metra M, Pagnesi M, Chioncel O, Davison B, Edwards C, Takagi K, Filippatos G, Tycińska A, Novosadova M, Gulati G, Barros M, Diaz ML, Guardia C, Zymliński R, Gajewski P, Ponikowski P, Simmons P, Simonson S, Cotter G. Biegus J, et al. Among authors: edwards c. J Heart Lung Transplant. 2025 Oct;44(10):1569-1580. doi: 10.1016/j.healun.2025.05.013. Epub 2025 May 30. J Heart Lung Transplant. 2025. PMID: 40451596 Clinical Trial.
Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis.
Davison BA, Abbate A, Cotter G, Pascual-Figal D, Van Tassell B, Villota JN, Atabaeva L, Freund Y, Aimo A, Biegus J, Golino M, Del Buono MG, Chioncel O, Cohen-Solal A, Edwards C, Fernández-Villa N, Filippatos G, González-Juanatey JR, Hayrapetyan H, Ibáñez B, Iborra PL, Moroni F, Ter Maaten JM, Markley R, González-Martín J, Martínez-Sellés M, Drambyan M, Metra M, Mirabet S, Mshetsyan A, Novosadova M, Pagnesi M, Ponikowski P, Riquelme-Pérez A, Sadoune M, Sánchez MA, Simon T, Taibo-Urquía M, Takagi K, Villar S, Liu C, Voors AA, Mebazaa A, Mann DL, Bayés-Genís A. Davison BA, et al. Among authors: edwards c. Heart Fail Rev. 2025 May;30(3):575-587. doi: 10.1007/s10741-025-10491-5. Epub 2025 Feb 12. Heart Fail Rev. 2025. PMID: 39939545
We examined current evidence regarding the effects of anti-inflammatory therapies in patients with acute heart failure (AHF) on the risk of cardiovascular outcomes, inflammatory markers, natriuretic peptides, and renal function. Despite growing evidence that inflammation p …
We examined current evidence regarding the effects of anti-inflammatory therapies in patients with acute heart failure (AHF) on the risk of …
100 results